Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07784699). This is a study registration, not published results. Lead sponsor: Gan & Lee Pharmaceuticals.. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 126 participants (ESTIMATED). Conditions: Healthy Subjects;Overweight or Obesity. Interventions: DRUG: GZC8072 Tablets; DRUG: Placebo. Primary outcome measures: Incidence of adverse events and serious adverse events , SAD:Baseline to Day36 MAD:Baseline to Day57; mmunogenicity: including anti-drug antibodies and neutralizing antibodies to GZC8072. , SAD:Baseline to Day36 MAD:Baseline to Day57. Brief summary: This trial is conducted in China. This study plans to include 2 parts, i.e., a single-dose study and a multiple-dose study: The single-dose study will be conducted in healthy adult participants to evaluate the safety, tolerability, and pharmacokinetic profile of single doses of GZC8072 Tablets; The multiple-dose study will be conducted in obese or overweight study participants to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of multiple doses of GZC8072 Tablets.